Therapeutic Benefits of Biophoton Therapy in Parkinson’s Disease: Clinical Evidence from a Pilot and Real-World Study

Authors

  • James Z Liu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Mariola Smotrys First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA  Author
  • Seth D Robinson Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Sherry Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Helen Y Gu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author

DOI:

https://doi.org/10.47363/JNRRR/2025(7)217

Keywords:

Parkinson’s Disease, Biophoton Therapy, Neurodegeneration, MDS-UPDRS, Neuroplasticity, Non-Invasive Treatment

Abstract

Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder lacking curative treatment. Biophoton therapy, a non-invasive modality utilizing ultra-weak photon emissions to restore cellular function, has shown promise in enhancing neurological recovery.

Objective: This study aimed to evaluate the clinical effects of automatic biophoton generators (ABG) on motor and non-motor symptoms in patients with PD.

Methods: A prospective, open-label pilot study enrolled 42 PD patients in both at home and wellness center settings. Participants received biophoton therapy for at least 8 hours daily over 2-4 weeks. Clinical outcomes were assessed using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the non-motor symptom scale (NMSS), Quality of Life (SF-36), and neurological examinations. Real-world feedback from 10 long-term ABG users was also analyzed.

Results: Biophoton therapy significantly improved motor function (reduced MDS-UPDRS scores), non-motor symptoms (lower NMSS scores), and quality of life (elevated SF-36 scores) within one week. No adverse events were reported. Improvements were consistent across both clinical and real-world groups, with enhanced energy, reduced tremors, and better sleep frequently cited. The detailed case demonstrated progressive neurological recovery, improved cognitive clarity, and increased biophoton levels over four weeks.

Conclusions: Biophoton therapy represents safe, effective, and non-invasive adjunct treatment for PD. Results suggest it may restore cellular energetics, reduce oxidative stress, and promote neuroplasticity. Larger randomized trials are warranted to confirm efficacy and optimize therapeutic protocols.

Author Biographies

  • James Z Liu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

  • Mariola Smotrys, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA 

    First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA 

  • Seth D Robinson, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Sherry Liu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

  • Helen Y Gu, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

    Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

Downloads

Published

2025-06-18

Issue

Vol. 7 No. 6 (2025): Volume 7 Issue 6

Section

Articles